Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HINT1 | P49773 | 4/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31011272 | 0.89 | HPGD (0.50) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL6512797 | 0.88 | HPGD (0.48) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL858664 | 0.88 | HPGD (0.54) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL15798398 | 0.87 | ADORA3 (0.49) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL6837868 | 0.87 | ADORA3 (0.49) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL4844756 | 0.84 | ADORA3 (0.51) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL546453 | 0.84 | ADORA3 (0.51) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL6537055 | 0.84 | ADORA3 (0.53) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL23883607 | 0.84 | HPGD (0.50) | HPGDADORA3HINT1NT5EADORA2A | |
| SCHEMBL6863967 | 0.84 | HPGD (0.50) | HPGDADORA3HINT1NT5EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | SIRNA THERAPEUTICS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | NSUN3, IRF3, SNRPF | HPGD 4616/4885ADORA3 109/4885HINT1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.